Versant Venture Management, LLC / CRSP
Versant Venture Management, LLC’s Crispr Therapeutics AG Position
Does Versant Venture Management, LLC own Crispr Therapeutics AG (CRSP)? Yes — 148.8K shares worth $7M (+5.01% of its 13F portfolio) as of Q1 2026.
Position Value
$7M
Q1 2026
Shares
148.8K
% of Portfolio
+5.01%
Quarters Held
30
currently held
Position History CRSP
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q1 2026 | 148.8K | $7M | +5.01% |
| Q4 2025 | 148.8K | $8M | +5.17% |
| Q3 2025 | 148.8K | $10M | +4.54% |
| Q2 2025 | 498.6K | $24M | +29.52% |
| Q1 2025 | 498.6K | $17M | +28.18% |
| Q4 2024 | 498.6K | $20M | +22.62% |
| Q3 2024 | 498.6K | $23M | +36.84% |
| Q2 2024 | 498.6K | $27M | +34.84% |
| Q1 2024 | 498.6K | $34M | +32.95% |
| Q4 2023 | 498.6K | $31M | +8.03% |
| Q3 2023 | 498.6K | $23M | +12.03% |
| Q2 2023 | 498.6K | $28M | +33.20% |
| Q1 2023 | 498.6K | $23M | +47.01% |
| Q4 2022 | 498.6K | $20M | +41.93% |
| Q3 2022 | 498.6K | $33M | +55.55% |
| Q2 2022 | 498.6K | $30M | +46.45% |
| Q1 2022 | 498.6K | $31M | +31.24% |
| Q4 2021 | 498.6K | $38M | +20.21% |
| Q3 2021 | 498.6K | $56M | +23.11% |
| Q2 2021 | 508.6K | $82M | +27.28% |
| Q1 2021 | 1.55M | $189M | +36.92% |
| Q4 2020 | 3.04M | $466M | +48.34% |
| Q3 2020 | 3.63M | $304M | +55.59% |
| Q2 2020 | 4.18M | $307M | +44.16% |
| Q1 2020 | 4.21M | $177M | +48.60% |
| Q4 2019 | 4.21M | $256M | +77.19% |
| Q3 2019 | 4.23M | $174M | +67.15% |
| Q2 2019 | 4.25M | $200M | +58.31% |
| Q1 2019 | 4.25M | $152M | +50.00% |
| Q4 2018 | 3.61M | $103M | +51.04% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Versant Venture Management, LLC’s full portfolio or all institutional holders of CRSP.